Boston Scientific (NYSE:BSX) said it's begun a clinical trial of its Ingevity next-generation pacemaker leads, designed to be safe for MRI procedures.

The Marlborough, Mass.-based medical device company said a patient in Sweden was the first enrollee in the trial, which is aimed at proving the safety and effectiveness of the devices in treating slow heartbeats or bradycardia.

The new leads are likely to be paired with Boston Scientific's Ingenio pacemaker line, according to a press release. The company is hoping the data from the 1,000-patient trial will back regulatory nods in the U.S. and the European Union, according to the release.